John E. Ultmann Professor of Medicine and Radiation Oncology, University of Chicago Medicine
Oncology
Dr. Everett E. Vokes, MD
|
|
Give Review
Everett Vokes practices Oncology. He received awards:"America's Top Doctors", "Chicago Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Elected Member" and "Super Doctor". Everett Vokes is a published doctor and has 101 publications published. The lastest was: 'Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Ch...
- Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer.
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic Carcinoma and for nonadenoid cystic malignant salivary tumors.
- Lung Cancer-a fractal viewpoint.
- Validation of survival prognostic models for non-small-cell lung Cancer in stage- and age-specific groups.
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-...
- Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- EGFR-based bioradiotherapy in SCCHN.
- Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell Carcinomas.
- A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung Cancer: Results of CALGB 30605 (A...
- Rare occurrence of EGFRvIII deletion in head and neck squamous cell Carcinoma.
- Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck Cancer.
- CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of adva...
- Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer.
- Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer.
- Survival and selected outcomes of older adults with locally advanced head/neck Cancer treated with chemoradiation therapy.
- Race and competing mortality in advanced head and neck Cancer.
- EGFR-directed treatments in SCCHN.
- Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: Relevance to lung Cancer.
- A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Dai...
- New radiotherapy and chemoradiotherapy approaches for non-small-cell lung Cancer.
- Competing roads to larynx preservation.
- A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck Cancer undergoing ...
- Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
- Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal Carcinoma.
- Non-Small-Cell Lung Cancer: Then and Now.
- Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung Cancer,...
- Critical role for the receptor tyrosine kinase EPHB4 in esophageal Cancers.
- Differential expression of RON in small and non-small cell lung Cancers.
- CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non-Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304.
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report.
- Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer.
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California...
- Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial.
- Chemoradiation for patients with large-volume laryngeal Cancers.
- Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
- Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study.
- Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary Gland malignancies.
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lu...
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck Cancer treated with concurrent chemotherapy and reirradiation.
- Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer.
- Response of human prostate Cancer cells and tumors to combining PARP inhibition with ionizing radiation.
- Dasatinib in previously treated metastatic colorectal Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck Cancers.
- Personalized treatment of lung Cancer.
- Proteomic characterization of non-small cell lung Cancer in a comprehensive translational thoracic oncology database.
- MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer.
- Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck Cancer.
- The epothilone B analogue ixabepilone in patients with advanced hepatobiliary Cancers: a trial of the University of Chicago Phase II Consortium.
- Chemoradiotherapy for locoregionally advanced squamous cell Carcinoma of the base of tongue.
- Temsirolimus has activity in non-mantle cell non-Hodgkin's Lymphoma subtypes: The University of Chicago phase II consortium.
- Phase II study of sunitinib malate in head and neck squamous cell Carcinoma.
- Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
- Gemcitabine plus sorafenib in patients with advanced pancreatic Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced Carcinoma of the esophagus or gastroesophageal junction.
- Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung Cancer (National Ca...
- Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck Cancer.
- EphA2 mutation in lung squamous cell Carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
- A phase II study of sorafenib in advanced uterine Carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung Cancer in patients with pulmonary dysfunction: CALGB 39904.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- Chemoradiation for patients with advanced oral cavity Cancer.
- CBL is frequently altered in lung Cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
- Predictors of competing mortality in advanced head and neck Cancer.
- Induction chemotherapy for head and neck Cancer: recent data.
- Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
- Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck Cancer.
- The role of EGFR inhibition in the treatment of non-small cell lung Cancer.
- Ethnic differences and functional analysis of MET mutations in lung Cancer.
- Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck Cancer.
- Cooperative group research endeavors in small-cell lung Cancer: current and future directions.
- Efficacy and safety of treating T4 Oral cavity tumors with primary chemoradiotherapy.
- PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy fol...
- A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung Cancer.
- Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell Carcinoma of the head and neck [corrected].
- The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell Carcinoma.
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell Carcinoma of the head and neck: a phase I/II study.
- PAX5 is expressed in small-cell lung Cancer and positively regulates c-Met transcription.
- Induction chemotherapy: to use or not to use? That is the question.
- Arsenic trioxide in patients with adenoCarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
- Expression and mutational analysis of MET in human solid Cancers.
- Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Thera...
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid Cancer: results from a phase II study.
- Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck Cancer.
- Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung Cancer.
- An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.
- Locally advanced non-small cell lung Cancer: the past, present, and future.
- Free-flap reconstruction in the doubly irradiated patient population.
- Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck Cancer.
- Introduction: head and neck Cancer.
- Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-sma...
- Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck Cancer.
- Combining radiotherapy with systemic therapies.
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
- Cooperative group portfolio in locally advanced non-small-cell lung Cancer: are we making progress?
- Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung Cancer: CALGB...
Schools
Rheinischen Friedrich Wilhelms Universitaet Bonn Medizinische Fakultat
University IlRavenswood Hospital
University Sthrn Ca Los Angeles Co Hospital
University of Chicago
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Sagamore Plus
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Elected Member
- Super Doctor
Education
-
University of Chicago -
University of Southern California - LAC+USC Medical Center -
University of Bonn Faculty of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1932262458 | |
| NPPES Provider LastName | VOKES | |
| NPPES Provider FirstName | EVERETT | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1932262458 |
| Last Name Of The Provider | VOKES |
| First Name Of The Provider | EVERETT |
| View All |
Similar Doctors
|
|
Dr. Edwin Posadas, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renee H. Jacobs, MD |
|
|
Dr. Dorothy Sipkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hedy L. Kindler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Ratain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rita Nanda, MD |
|
|
Dr. Ezra E. Cohen, MD |